In a report released today, Eliana Merle from Cantor Fitzgerald maintained a Buy rating on AnaptysBio Inc (NASDAQ: ANAB), with a price target of $140. The company’s shares closed yesterday at $75.95.
Merle said:
“. $140 price target. We think positive Dupixent phase 3 nasal polyp data from REGN (Neutral)/SNY (Not Covered) is an incremental positive for ANAB as it helps de-risk ANAB’s readout in this indication in 2H 2019. ANAB is also studying etokimab in chronic sinusitis with nasal polyps (CSwNP) and is guiding for phase 2 data in 2H19 (n=100, placebo controlled study). Because of the similarities in Dupixent and etokimab mechanisms of actions, we believe this should increase the likelihood of etokimab’s success in this study.”
According to TipRanks.com, Merle is ranked #3587 out of 4887 analysts.
AnaptysBio Inc has an analyst consensus of Strong Buy, with a price target consensus of $133.50.
See today’s analyst top recommended stocks >>
Based on AnaptysBio Inc’s latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $13.62 million. In comparison, last year the company had a GAAP net loss of $9.09 million.
Based on the recent corporate insider activity of 9 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of ANAB in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
AnaptysBio, Inc. is a clinical stage biotechnology company, which engages in developing antibody product candidates focused on unmet medical needs in inflammation. Its pipeline includes ANB020, ANB019, and checkpoint receptor agonist antibodies.
